Ebola Vaccine Human Trials Funded By Global Consortium Begin

Dr Felicity Hartnell injects the vile of the ebola vaccine called Chimp Adenovirus type 3 (ChAd3) to Ruth Atkins, who is the first healthy UK volunteer to receive an...
dr-felicity-hartnell-injects-ebola-vaccine-oxford-university
Dr Felicity Hartnell, who is a clinical research fellow at Oxford University, injects the vile of the ebola vaccine called Chimp Adenovirus type 3 (ChAd3) to Ruth Atkins, who is the first healthy UK volunteer to receive an ebola vaccine.
SHARE THIS STORY:

Glaxo Smith Kline announces unprecedented global consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in west Africa.

dr-felicity-hartnell-injects-ebola-vaccine-oxford-university

Dr Felicity Hartnell, who is a clinical research fellow at Oxford University, injects the vial of the Ebola vaccine called Chimp Adenovirus type 3 (ChAd3) to Ruth Atkins, who is the first healthy UK volunteer to receive an ebola vaccine.

Human trials of this candidate vaccine, being co-developed by the US National Institutes of Health (NIH) and GlaxoSmithKline, are to be accelerated with funding from an international consortium in response to the Ebola epidemic, which the World Health Organization recently declared a public health emergency of international concern.

A £2.8 million grant from the Wellcome Trust, the Medical Research Council (MRC) and the UK Department for International Development (DFID) will allow a team led by Professor Adrian Hill, of the Jenner Institute at the University of Oxford, to start safety tests of the vaccine alongside similar trials in the USA run by the National Institute of Allergy and Infectious Diseases (NIAID, a part of the NIH).

The phase 1 trials will begin as soon as they receive ethical and regulatory approvals, which will be considered on an expedited basis. If approvals are granted, the UK research teams could start vaccinating volunteers from mid-September.

NTEB is run by end times author and editor-in-chief Geoffrey Grider. Geoffrey runs a successful web design company, and is a full-time minister of the gospel of the Lord Jesus Christ. In addition to running NOW THE END BEGINS, he has a dynamic street preaching outreach and tract ministry team in Saint Augustine, FL.
SUBSCRIBE NOW

End times Bible prophecy news happens fast, add your email now to get our latest articles sent to your inbox in real-time.

Join 12,774 other subscribers

SUPPORT NTEB

24 hours a day, seven days per week, Now The End Begins keeps you informed of what's happening around the world as it relates to the end times and Bible prophecy. Your generous non-tax deductible contribution helps us to do that. Thank you in advance for your much-needed support.